Definium Therapeutics (DFTX) jumps in premarket on Phase 3 depression trial

Definium Therapeutics Inc. surged in pre-market trading after the company said its LSD-based DT120 tablet hit the main target in a late-stage depression trial. The New York biotech traded at $40.19 on Public.com at 9:00 a.m. ET, up 64.2% from Friday’s close of $24.48. Nasdaq’s session hadn’t started yet, with the open set for 9:30 a.m. ET.

NASDAQ:CMPS · NASDAQ:DFTX · Stock Market
Compass Pathways Rallies Pre-Market on FDA Trade Speculation

Compass Pathways Rallies Pre-Market on FDA Trade Speculation

Compass Pathways plc jumped in U.S. premarket action Monday as the stock built on last week’s gains. Investors are reacting to signs of a quicker path for COMP360, the company’s psilocybin drug candidate for depression. The Nasdaq shares traded at $12.39 at 6:03 a.m. EDT, up 19.5% from Friday’s close at $10.37. Regular trading on Nasdaq begins at 9:30 a.m. Eastern.
18 May 2026
·
Follow on Google News
Add as preferred source Open in Google News